The purpose of this study is to collect data. The sponsor will be collecting medical information from study participants (through an interview and a phone call up to 7 days after the last infusion) to evaluate the occurrence of Aseptic Meningitis Syndrome (AMS) in an adult population (≥ 18 years of age) treated with ≥1g/kg Intragam 10.
AMS is an illness characterized by inflammation of the linings of the brain. Symptoms vary, with headache and fever most common. The illness is usually mild and runs its course without treatment; however, some cases can be severe.
The study will be performed in Australia in about 15 centres and approximately 200 patients will be enrolled in the study.